|
|
|
The Iverson HPV Panel has the capability to individually detect 26 of the most significant human papilloma virus (HPV) genotypes. With this information, health care providers can make more informed choices in the care of HPV infected patients in the fight against cervical cancer. HPV and Cervical Cancer- Cervical Cancer is the second most common cancer in women
- High risk HPV types are detected in 99% of cervical cancers 1
- An estimated 26.8% of US females (age 14 to 59) had HPV infections 2
- 70% of the world's cervical cancer is caused by types 16 and 18 3, 4
- Identifying types 16 and 18 infections may be a better predictor of CIN3* and cervical cancer than current cytological methods (ASCUS or LSIL*) 4
- Types 59 and 33 are also considered "high risk" for cervical cancer 5
- Infections with multiple HPV types can compound risk of developing cervical cancer
- HPV genotype should be considered in post CIN-treatment monitoring policies 6
- Early diagnosis of HPV infection and identification of high-risk HPV genotypes, can help health care providers individualize treatment and may help prevent cervical cancer
Terms (*)
CIN3: cervical intraepithelial neoplasia grade 3
ASCUS: atypical squamous cells of undetermined significance
LSIL: low-grade squamous intraepithelial lesion
References
- Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
- E.F. Dunne, et al., Prevalence of HPV Infection Among Females in the United States, JAMA, Feb.28, 2007, Vol.297, No. 8, pp. 813-819.
- Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;(31):3-13.
- M.J.Khan, etal. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, JNCI, Vol.97, No.14, p.1072-1079, July 20, 2005.
- X.Castellsague, et al., Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention, JNCI, Vol.98, No.5, p.303-315, March 1, 2006
- G M, et al. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol. 2007 Feb;104(2):273-5. Epub 2006 Dec 8.
|
|
|
|
|
|
|
|
|
Rapid turn-around time
You will have your test results within 96 hours of sample submission.
Reduced Patient Costs
Our automated INFINITI processing technology reduces the requirement for continuous operator involvement in sample processing, thus saving you money.
Diagnostic Accuracy
We identify the exact genetic variant in order to assess risk and allow you the ability to address potential threats before they manifest themselves.
|
|
|
